Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Pipeline Review, H2 2018

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Pipeline Review, H2 2018


  • Products Id :- GMDHC1636TDB
  • |
  • Pages: 67
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)-Pipeline Review, H2 2018

Summary

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) pipeline Target constitutes close to 11 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Cyclin Dependent Kinase 2-Pipeline Review, H2 2018, outlays comprehensive information on the Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)-Cyclin-dependent kinase 2 is an enzyme encoded by the CDK2 gene. CDK2 is the catalytic subunit of the cyclin-dependent protein kinase complex which regulates progression through the cell cycle. Activity of CDK2 is especially critical during the G1 to S phase transition. CDK2 associates with and regulated by other subunits of the complex including cyclin A or E, CDK inhibitor p21Cip1 (CDKN1A), and p27Kip1 (CDKN1B). The molecules developed by companies in Phase II, Phase I and Preclinical stages are 5, 1 and 2 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Ear Nose Throat Disorders, Hematological Disorders, Immunology, Infectious Disease, Metabolic Disorders and Respiratory which include indications Breast Cancer, Lung Cancer, Metastatic Hepatocellular Carcinoma (HCC), Neuroblastoma, Ovarian Cancer, Pancreatic Cancer, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Astrocytoma, Bleeding And Clotting Disorders, Chronic Lymphocytic Leukemia (CLL), Cystic Fibrosis, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Gliosarcoma, Hearing Disorders, Laryngeal Cancer, Mantle Cell Lymphoma, Multiple Myeloma (Kahler Disease), Pituitary ACTH Hypersecretion (Cushing Disease), Pseudomonas aeruginosa Infections, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis, Thymic Carcinoma and Uterine Cancer.

Furthermore, this report also reviews key players involved in Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)

- The report reviews Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects

- The report assesses Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)-Overview

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)-Companies Involved in Therapeutics Development

Astex Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc

Tiziana Life Sciences Plc

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)-Drug Profiles

AT-7519-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCT-68127-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CYC-065-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JRP-890-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

kenpaullone-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

milciclib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sapacitabine + seliciclib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seliciclib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK2 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDK2 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-02-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)-Dormant Products

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)-Discontinued Products

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)-Product Development Milestones

Featured News & Press Releases

Jun 14, 2018: Lees Pharmaceutical Holdings: Update on An Investigational Oncology Product

May 16, 2018: Tiziana Life Sciences Announces Interim Analysis Data from an Ongoing Phase 2a Trial of Milciclib Safety and Tolerability in Sorafenib-refractory or -intolerable, Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Patients

Apr 17, 2018: Cyclacel's CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia

Apr 16, 2018: Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting

Apr 09, 2018: Tiziana Life Sciences Announces a Poster Presentation on Phase II clinical data with Milciclib in Thymic carcinoma and Thymoma patients at the American Society of Clinical Oncology (ASCO) Meeting (June 1-5, Chicago IL)

Mar 15, 2018: Phase 1 Clinical Data With Cyclacel's CYC065 CDK Inhibitor Have Been Selected for Oral Presentation at AACR 2018 Annual Meeting

Dec 08, 2017: Tiziana Life Sciences Announces Safety of Milciclib in a Phase 2a Trial in Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Patients

Nov 23, 2017: Tiziana Life Sciences Announces that Milciclib Met its Primary Endpoint in Two Phase II Clinical Trials in Patients with Thymic Carcinoma and Thymoma

Sep 26, 2017: Powerful Drug Combo Gangs Up to Tackle Triple-Negative Breast Cancer

Aug 07, 2017: Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression

Jul 19, 2017: Tiziana Life Sciences Announces Initiation of a Phase IIa Clinical Trial with Milciclib in Patients with Hepatocellular Carcinoma

Apr 24, 2017: Tiziana Life Sciences Announces Approval of a Phase II Clinical Trial Protocol for Milciclib in Patients with Hepatocellular Carcinoma

Apr 21, 2017: Tiziana Life Sciences Announces Publication of Peer-Reviewed Paper from Positive Clinical Trial of Milciclib in Patients with Refractory Solid Tumours

Apr 02, 2017: Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways

Mar 07, 2017: Cyclacels CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of Action, in Research Published in JNCI

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Astex Pharmaceuticals Inc, H2 2018

Pipeline by Cyclacel Pharmaceuticals Inc, H2 2018

Pipeline by Tiziana Life Sciences Plc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Dormant Products, H2 2018 (Contd..2), H2 2018

Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Astex Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc

Tiziana Life Sciences Plc

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) Therapeutic Products under Development, Key Players in Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) Therapeutics, Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) Pipeline Overview, Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) Pipeline, Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) Pipeline Assessment

select a license
Single User License
USD 3500 INR 240170
Site License
USD 7000 INR 480340
Corporate User License
USD 10500 INR 720510

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com